盐酸吡格列酮对2型糖尿病患者血清基质金属蛋白酶-9水平影响研究

Effects of Pioglitazone on Serum Matrix Metalloproteinase-9 Levels in Patients with Type 2 Diabetes

目的观察胰岛素增敏剂吡格列酮对2型糖尿病(2DM)患者血清基质金属蛋白酶-9(mmp-9)水平的影响。方法60例伴有轻度大血管并发症的2DM患者,随机、双盲分成吡格列酮组(A组30例),对照组(B组30例),进行平行对照的盐酸吡格列酮临床研究,采用酶联免疫吸附法(ELISA)测定盐酸吡格列酮治疗12周前后血清mmp-9水平。结果(1)经过12周治疗,吡格列酮组血清mmp-9水平下降了19.8%。(2)吡格列酮组治疗后各指标水平均较对照组差异有显著性意义(P<0.01)。结论盐酸吡格列酮可降低2DM患者血清mmp-9水平,有助于防治2型糖尿病患者大血管并发症。

Objective To evaluate the effects of pioglitazone, an insulin sensitizing agent, on serum matrix metalloproteinase - 9 （ mmp-9） levels in patients with type 2 diabetes. Methods Type 2 diabetic patients （ n = 60） with mild vascular complication were divided as pioglitazone group （ n = 30） and control group （ n = 30） at random and in double-blind. The concurrently controlled clinical study was done about pioglitazone between pre-and post -12 weeks＇treatment, and mmp-9 level was detected by ELISA method. Results （ 1 ） After 12 weeks＇treatment, the level of romp -9 in pioglitazone group was reduced by 19. 8%, there was a significant difference compared with that before treatment （ P 〈0. 01 ） ; but there was no significant difference in the level of romp-9 between pre-and post-the treatment in the control group. （2） After 12 weeks＇treatment, serum insulin levels, fasting blood glucose, hemoglobin Alc, and fasting triglyceride decreased in pioglitazone group （ P 〈 0. 01 ）. Conclusion Pioglitazone could reduce fasting serum romp-9 levels in type 2 diahetic patients and improve the vascular complications.